June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Efficacy and safety of an Iontophoresis platform to control post cataract inflammation and pain
Author Affiliations & Notes
  • Barbara M Wirostko
    EyeGate Pharmaceutical, Inc, Salt Lake City, Utah, United States
  • Carol Marie Assang
    EyeGate Pharmaceutical, Inc, Salt Lake City, Utah, United States
  • Brenda Mann
    EyeGate Pharmaceutical, Inc, Salt Lake City, Utah, United States
  • Stephen From
    EyeGate Pharmaceutical, Inc, Salt Lake City, Utah, United States
  • Michael Raizman
    Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Barbara Wirostko, EyeGate (F), EyeGate (I), EyeGate (E), EyeGate (S); Carol Assang, EyeGate (E), EyeGate (I); Brenda Mann, EyeGate (F), EyeGate (I), EyeGate (E), EyeGate (S); Stephen From, EyeGate (F), EyeGate (I), EyeGate (E), EyeGate (S); Michael Raizman, EyeGate (F), EyeGate (I), EyeGate (S), EyeGate (R), EyeGate (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1081. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Barbara M Wirostko, Carol Marie Assang, Brenda Mann, Stephen From, Michael Raizman; Efficacy and safety of an Iontophoresis platform to control post cataract inflammation and pain. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1081.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine safety and efficacy of EGP-437 (dexamethasone phosphate solution) delivered via a novel and proprietary iontophoresis platform, the EyeGate II Delivery System, for managing post-surgical inflammation and pain.

Methods : This clinical study was conducted as an open label design with 7 active cohorts (N= 69 patients), varying the iontophoretic dose and dosing regimen as described in Table 1, receiving a 40 mg/ml solution of dexamethasone phosphate. An additional cohort (N=10 patients) received sodium citrate buffer as a placebo #8. Aqueous samples were collected from half of the patients (N=5) from cohort #7 at time of surgery to assess ocular bioavailability of the dexamethasone. The primary endpoint for all cohorts was Anterior Chamber Cell count (ACC) at day 14, with secondary endpoints of pain and intra-ocular pressure. Patients were followed for 28 days post-surgery.

Results : The iontophoretic dose and treatment regimens for cohorts 2 and 6 resulted in a larger percentage of patients with an ACC of zero at day 14 (30% and 40%, respectively) compared to the placebo group (20%). At day 28, 80% of patients in cohort 2 and 70% in cohort 6 had an ACC = 0. In the placebo group, 80% of the patients had to be rescued prior to day 14. The aqueous samples from cohort 7 had 20.03 ± 8.53 ug/mL of total dexamethasone present. A majority of patients in cohorts 1-7 had a pain score of zero on day 1. Further, no elevation of IOP was noted in these cohorts and the delivery was well tolerated.

Conclusions : Iontophoretic delivery of EGP-437 was demonstrated to be a safe method to deliver adequate amounts of steroid into the ocular tissue to successfully manage post cataract inflammation and pain. This technology has the potential to eliminate the daily need for corticosteroid eye drops, thus leading to improved outcomes for this large patient population.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Table 1: Cohort Dosing Regimen for EGP-437

Table 1: Cohort Dosing Regimen for EGP-437

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×